Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

icient method for producing Id/KLH immunotherapies, but also the added advantage of making them potentially more active as well."

About FavId

FavId is a patient-specific, Id/KLH active immunotherapy for the treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase 3 clinical trial of FavId following Rituxan(R) induction therapy in patients with follicular B-cell NHL in January 2006. Analysis of the primary endpoint, time to disease progression, is event driven and currently projected to occur during the fourth quarter of 2007. The Company has a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for its Phase 3 trial, and has also received Fast Track designation for FavId from the FDA.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "Investment Analysis of the ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the US medical device sector identifies the key ... venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... March 17 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... ended December 31, 2007, and provided an update,on the ... "During 2007 and the first quarter of 2008, we ... an important transitional year for,Alexza, as we initiate the ...
... Eye via,Ophthalmic Artery, WASHINGTON, March 17 ... -- a,deadly, inherited cancer of one or both ... having their eyes surgically removed (enucleated),according to the ... Society of,Interventional Radiology,s 33rd Annual Scientific Meeting. Advanced,retinoblastoma ...
Cached Medicine Technology:Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 2Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 3Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 4Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 5Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 6Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 7Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 8Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 9Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 10Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 11Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 12Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 13Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status 14New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 2New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 3New Localized Cancer Treatment for Advanced Retinoblastoma Saves Children From Having Eyes Removed, Restores Vision in Some Cases 4
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- Adults who experienced ... of migraine headaches, suggests a study published online ... "Childhood maltreatment can have long-lasting effects, like ... adulthood," study author Dawn Buse, director of behavioral ... City, said in a journal news release. ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, ... likely to start smoking or drinking with each additional ... conduct disorder, new research suggests. "Our findings ... of substance use as [these] children approach adolescence," said ... Pediatric Research Group, which is part of Cincinnati Children,s ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... from the American Diabetes Association (ADA) call for giving the ... to help prevent heart disease. These new standards bring ... and American Heart Association, which also recommend giving low- or ... including people with diabetes. "We agree that the decision ...
(Date:12/24/2014)... ladies, new fashionable outfits are necessary when heading into a ... Angeldress.co.uk has chosen some of their best dresses ... by launching a promotion on its cheap clothes and fashion ... off, like a cheap suit. , “All items are in ... are among the hottest items in the global market. They ...
(Date:12/24/2014)... 2014 Dr. Svetlana Gomer, MGS Tewksbury ... nation gathered with US Marines on November 14, 2014 ... for the Toys for Tots Literacy Program. This ... new books and audio books for the Toys for ... this Christmas. It represents another major strike in the ...
Breaking Medicine News(10 mins):Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Court on Monday upheld a ban on a teenager from wearing ... sex before marriage. ,Lydia Playfoot, 16, said she ... school, the Millais School in Horsham, West Sussex, denies infringing her ... of the Christian faith and violates its uniform policy. ...
... Illinois at Chicago have created a theoretical blueprint for ... , ,Scientists say the propeller opens the possibility ... out of cells. ,, ,Petr Krl, Assistant ... used classical molecular dynamics simulations to learn how tiny ...
... webcams and other new technological innovations have transformed the ... an international congress of the deaf said Tuesday. ... the internet, internet, webcams, email, SMS and chat ... institute for the deaf in the eastern city of ...
... the world. Perhaps one way out could be treating everyone ... , Sir Liam Donaldson, Englands Chief Medical Officer has suggested. ... leads to the deaths of hundreds of patients on waiting ... cent of people want to donate their organs after death, ...
... to a study published Neurology, the medical journal of the ... perform worse in school than healthy kids , grades in ... harder time than boys in getting good grades. ... grades and subjects of brain tumor survivors have been reported. ...
... A few months back, the Food and Drug Administration approved ... effective at preventing pregnancy as the other pills already in ... who take it will never get their periods. ... may never be the same- it may disappear altogether. ...
Cached Medicine News:Health News:New Technology Transforming Life for the Deaf 2Health News:Treat Every Patient as a Potential Organ Donor, British Health Official Says 2Health News:Brain Tumor Children Poor Performance in Schools 2Health News:The Queen Of All Contraceptives Released 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: